Empowering clinicians with AI medical technologies that solve real challenges.
About Us
Keya Medical is an international medical technology company specializing in deep learning-based solutions for cardiovascular diagnosis. Its flagship product, DEEPVESSEL FFR, is an FDA-cleared, CE-marked, NMPA-approved, and certified by HSA of Singapore CT-FFR analysis that provides non-invasive coronary artery assessment using CCTA.
To learn more about Keya Medical, follow us on LinkedIn, Twitter, and Facebook.
Certifications of CT FFR Analysis – DEEPVESSEL FFR
NMPA
January 2020
CE
August 2018
FDA
April 2022
HSA
July 2023
Comprehensive R&D Pipeline Solution Suites
Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment followup.
By the Numbers
Employees
Collaboration Partners
Registered Patents
Milestones
2016
Keya Medical is founded
2017
Keya Medical establishes the first AI diagnostic laboratory
2018
DeepVessel FFR enters the CFDA Special Approval Channel for Innovative Medical Devices
Keya Medical receives ISO 13485 certification
DeepVessel FFR receives CE Mark
2019
Keya Medical is selected to the Top 100 Medical Companies of the Future list by VCBeat Research
2020
DeepVessel FFR becomes the first Class-III AI medical device approved for clinical use by the Chinese National Medical Products Administration
$15 million in strategic funding
$20 million in Series B+ funding
$30 million in Series C funding
$46 million in Series D funding
2021
DeepVessel FFR demonstrates an accuracy of 92% in a single-center retrospective study conducted by researchers at Fuwai Hospital
2022
ADAPT clinical trial is completed
DeepVessel FFR received FDA clearance
2023
The TARGET Randomized Trial presented at Late-breaking science at ACC 2023
2024
DeepVessel FFR joins Calantic (Bayer) AI platrform
2023
DeepVessel FFR receives Singapore HSA certification
